SCHEMBL8108400

SCHEMBL8108400

C[N+]1(CCCS(=O)(=O)[O-])CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CDC25A P30304 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
BBOX1 O75936 3/20 0.35
CYP2C9 P11712 1/20 0.35
TERT O14746 6/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
APOBEC3A P31941 2/20 0.33
APOBEC3G Q9HC16 2/20 0.33
PABPC1 P11940 1/20 0.33
GMNN O75496 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
THPO P40225 1/20 0.33
HBB P68871 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15819766 0.95 HPGD (0.41) HPGDALOX15CDC25ACTDSP1L3MBTL1
SCHEMBL1283707 0.83 HPGD (0.42) HPGDALOX15CDC25ACTDSP1L3MBTL1
SCHEMBL5009177 0.82 BBOX1 (0.47) HPGDALOX15CDC25ACTDSP1BBOX1
Sulfuric Acid SCHEMBL17102678 0.81 CDC25A (0.50) HPGDALOX15CDC25ACTDSP1L3MBTL1
SCHEMBL2396073 0.81 BBOX1 (0.46) HPGDCDC25ACTDSP1BBOX1TERT
Sulfuric Acid SCHEMBL17102648 0.79 CDC25A (0.48) HPGDALOX15CDC25ACTDSP1L3MBTL1
SCHEMBL10256880 0.78 HPGD (0.41) HPGDALOX15CDC25ACTDSP1L3MBTL1
SCHEMBL9935685 0.77 HPGD (0.58) HPGDALOX15CDC25ACTDSP1L3MBTL1
SCHEMBL5011415 0.77 BBOX1 (0.46) HPGDCDC25ACTDSP1BBOX1SMN1; SMN2
SCHEMBL17102598 0.76 CDC25A (0.49) HPGDALOX15CDC25ACTDSP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230101362-A1 RNA STABILIZATION TEAM MEDICAL LLC 2023-03-30 US claimed
EP-4361621-B1 SAMPLE ANALYSIS METHOD, CAPILLARY ELECTROPHORESIS SOLUTION, AND SAMPLE ANALYSIS KIT ARKRAY INC (JP) 2026-04-08 EP disclosed
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 US disclosed
US-20240159769-A1 SAMPLE ANALYSIS METHOD, SAMPLE PRODUCTION METHOD, DILUENT FOR DILUTING ALBUMIN- AND y-GLOBULIN-CONTAINING SAMPLE, AND SAMPLE ANALYSIS KIT ARKRAY, INC. (JP) 2024-05-16 US disclosed
US-20240159705-A1 SAMPLE ANALYSIS METHOD, CAPILLARY ELECTROPHORESIS SOLUTION, AND SAMPLE ANALYSIS KIT ARKRAY, INC. (JP) 2024-05-16 US disclosed
EP-4361622-A1 SAMPLE ANALYSIS METHOD, SAMPLE PRODUCTION METHOD, DILUENT FOR DILUTING ALBUMIN- AND GAMMA-GLOBULIN-CONTAINING SAMPLE, AND SAMPLE ANALYSIS KIT ARKRAY, Inc. (JP) 2024-05-01 EP disclosed
EP-4361621-A1 SAMPLE ANALYSIS METHOD, CAPILLARY ELECTROPHORESIS SOLUTION, AND SAMPLE ANALYSIS KIT ARKRAY, Inc. (JP) 2024-05-01 EP disclosed
US-20240115595-A1 MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY TEAM MEDICAL, LLC (US) 2024-04-11 US disclosed
WO-2024055011-A1 MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY TEAM MEDICAL, LLC (US) 2024-03-14 WO disclosed
US-20230101362-A1 RNA STABILIZATION TEAM MEDICAL LLC 2023-03-30 US disclosed
WO-2023044455-A2 RNA STABILIZATION TEAM MEDICAL LLC (US) 2023-03-23 WO disclosed
EP-3249054-A1 FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS Biomatrica, INC. (US) 2017-11-29 EP disclosed
US-9725703-B2 Formulations and methods for stabilizing PCR reagents BIOMATRICA, INC. (US) 2017-08-08 US disclosed
US-20150329849-A1 FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS MXCGLOBAL INC. 2015-11-19 US disclosed
EP-1048669-A1 CARBAPENEM DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240115595-A1 MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY RBM22, HNRNPUL2, HNRNPUL1 HPGD 4599/4885ALOX15 3609/4885CDC25A 3728/4885
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 HPGD 4461/4885ALOX15 1547/4885CDC25A 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.